Association of cardiometabolic risk factors and hepatic enzymes in a national sample of iranian children and adolescents: The CASPIAN-III study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 4, 2014, Pages 463-468

  Mohammadi, Fatemeh ^a   Qorbani, Mostafa ^b   Kelishadi, Roya ^c   Baygi, Fereshteh ^d   Ardalan, Gelayol ^c   Taslimi, Mahnaz ^d   Mahmoudarabi, Minoosadat ^d   Motlagh, Mohammad Esmaeil ^e   Asayesh, Hamid ^f   Larijani, Bagher ^d   Heshmat, Ramin ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f QOM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

alanine aminotransferase; aspartate aminotransferase; cardiometabolic risk factors; metabolic syndrome; pediatric

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOMETABOLIC RISK; CHILD; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ELEVATED BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEALTH SURVEY; HUMAN; IRAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL EXAMINATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; HYPERTENSION; OBESITY, ABDOMINAL; RISK FACTOR;

ADOLESCENT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTENSION; IRAN; MALE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; RISK FACTORS; TRIGLYCERIDES;

EID: 84897395355     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000246     Document Type: Article

References (40)

1. Lioudaki ES, Ganotakis EP, Mikhailidis D. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011;17:3632-43.
2. Zhang Y, Lu X, Hong J, et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocrine 2010;38:181-7.
3. Fraser A, Longnecker M, Lawlor D. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007;133:1814-20.
4. Kelishadi R, Cook SR, Adibi A, et al. Association of the components of the metabolic syndrome with non-Alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Dia-betol Metab Syndr 2009;1:29-38.
5. Park HS, Han JH, Choi KM, et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005;82:1046-51.
6. Salamone F, Galvano F, Li Volti G. Insulin resistance links nonalcoholic fatty liver to cardiovascular diseases. Hepatology 2011;53:1785-6.
7. Elinav E, Ben-Dov I, Ackerman E, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol 2005;100:2201-4.
8. Pratt D, Kaplan M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
9. Boansah LM, Balistreri WF. Manifestation of liver disease. In: Klieg-man RM, Stanton BF, Schor NF, eds. Nelson Textbook of Pediatrics. 19th ed et al. Phyladelphia: Elsevier Saunders; 2011:1374-81.
10. Jamali R, Pourshams A, Amini S, et al. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med 2008;11:602-7.
11. Kelishadi R, Heshmat R, Motlagh ME, et al. Methodology and early findings of the third survey of CASPIAN study: a national school-based surveillance of students' high risk behaviors. Int J Prev Med 2012; 3:394-401.
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-76.
13. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987; 166:1-8.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Kelishadi R, Abtahi S-H, Qorbani M, et al. First National Report on Aminotransaminases' Percentiles in Children of the Middle East and North Africa (MENA): the CASPIAN-III Study. Hepat Mon 2012; 12:e7711.
16. Kawamoto R, Kohara K, Kusunoki T, et al. Alanine aminotransferase/ aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol 2012; 11:117-25.
17. Hanley AJ, Wagenknecht LE, Festa A, et al. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2007; 30:1819-27.
18. Homsanit M, Sanguankeo A, Upala S, et al. Abnormal liver enzymes in Thai patients with metabolic syndromes. J Med Assoc Thai 2012; 95:444-51.
19. Cook S, Auinger P, Li C, et al. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. J Pediatr 2008;152:165-70.
20. Kelishadi R, Gouya M, Ardalan G, et al. CASPIAN Study Group: first reference curves of waist and hip circumferences in an Asian population of youths: CASPIAN study. J Trop Pediatr 2007;53:158-64.
21. El-Koofy N, Anwar G, El-Raziky M, et al. The association of metabolic syndrome, insulin resistance and non-Alcoholic fatty liver disease in overweight/obese children. Saudi J Gastroenterol 2012;18:44-9.
22. Zimmet P, Alberti K, Kaufman F, et al. The metabolic syndrome in children and adolescents-An IDF consensus report. Pediatr Diabetes 2007;8:299-306.
23. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8.
24. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
25. Wu X-Y, Hu C-L, Wan Y-H, et al. Higher waist-to-height ratio and waist circumference are predictive of metabolic syndrome and elevated serum alanine aminotransferase in adolescents and young adults in Mainland China. Public Health 2012;126:135-42.
26. Patel D, Srinivasan S, Chen W, et al. Serum alanine aminotransferase and its association with metabolic syndrome in children: the Bogalusa Heart Study. Metab Syndr Relat Disord 2011;9:211-6.
27. Kong A, Choi K, Cockram C, et al. Independent associations of alanine aminotransferase (ALT) levels with cardiovascular risk factor clustering in Chinese adolescents. J Hepatol 2008;49:115-22.
28. ÇagdasAyvaz DN, NisanciKilink F, Pac FA, et al. Anthropometric measurements and body composition analysis of obese adolescents with and without metabolic syndrome. Turk J Med Sci 2011; 4: 267-74.
29. Schwimmer J, McGreal N, Deutsch R, et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005;115:561-5.
30. Wickramasinghe VP, Silva KSH, Goonaratne INA, eds. Paper presented at: 8th Commonwealth Congress on Diarrhoea and Malnutrition, Commonwealth Association for Paediatric Gastroenterology and Nutrition-CAPGAN; Dhaka, Bangladesh; February 5-9, 2006.
31. Meccawy AA. Multiple risk factors for non-Alcoholic fatty liver disease in obese children and adolescents. Webmed Central GENERAL MEDICINE 2011;2:WMC001926.
32. Calcaterra V, Muratori T, Klersy C, et al. Early-onset metabolic syndrome in prepubertal obese children and the possible role of alanine aminotransferase as marker of metabolic syndrome. Ann Nutr Metab 2011;58:307-14.
33. Musso G, Gambino R, Cassader M. Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology 2011;53:1773.
34. Musso G, Gambino R, Cassader M, et al. Meta-Analysis: natural history of non-Alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
35. Targher G, Day C, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
36. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010;52:1156-61.
37. Yilmaz Y, Kurt R, Kalayci C. Liver enzymes and cardiovascular outcomes: a new research agenda. Hepatology 2010;52:2242.
38. Kelishadi R, Poursafa P. Obesity and air pollution: global risk factors for pediatric non-Alcoholic fatty liver disease. Hepat Mon 2011;11:794-802.
39. Shen L. Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease. Hepatology 2011;54:377-8.
40. Targher G, Day C. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. Hepatology 2011;53:375.